Cargando…
Impact of WIN site inhibitor on the WDR5 interactome
The chromatin-associated protein WDR5 is a promising pharmacological target in cancer, with most drug discovery efforts directed against an arginine-binding cavity in WDR5 called the WIN site. Despite a clear expectation that WIN site inhibitors will alter the repertoire of WDR5 interaction partners...
Autores principales: | Guarnaccia, Alissa D., Rose, Kristie L., Wang, Jing, Zhao, Bin, Popay, Tessa M., Wang, Christina E., Guerrazzi, Kiana, Hill, Salisha, Woodley, Chase M., Hansen, Tyler J., Lorey, Shelly L., Shaw, J. Grace, Payne, William G., Weissmiller, April M., Olejniczak, Edward T., Fesik, Stephen W., Liu, Qi, Tansey, William P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7871196/ https://www.ncbi.nlm.nih.gov/pubmed/33472061 http://dx.doi.org/10.1016/j.celrep.2020.108636 |
Ejemplares similares
Ejemplares similares
-
Targeting WDR5: A WINning Anti-Cancer Strategy?
por: Aho, Erin R, et al.
Publicado: (2019) -
Synergistic action of WDR5 and HDM2 inhibitors in SMARCB1-deficient cancer cells
por: Florian, Andrea C, et al.
Publicado: (2022) -
WIN site inhibition disrupts a subset of WDR5 function
por: Siladi, Andrew J., et al.
Publicado: (2022) -
WDR5 is a conserved regulator of protein synthesis gene expression
por: Bryan, Audra F, et al.
Publicado: (2020) -
Multiple interactions of the oncoprotein transcription factor MYC with the SWI/SNF chromatin remodeler
por: Woodley, Chase M., et al.
Publicado: (2021)